T-NBOMe, or TNBOMe, also known as NBOMe-T, NBOMe-tryptamine, or N-(2-methoxybenzyl)tryptamine, is a serotonin receptor modulator and possible psychedelic drug of the tryptamine family. It is the N-(2-methoxybenzyl) derivative of tryptamine.
The drug shows affinity for the serotonin 5-HT2 receptors, including for the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors (Ki = 89nM, 47nM, and 224nM, respectively). It shows 46-fold higher affinity for the serotonin 5-HT2A receptor than tryptamine (Ki = 89nM vs. 4,074nM, respectively). T-NBOMe acts as a partial agonist of the serotonin 5-HT2A receptor ( = 1,549nM; = 63%) and as a near-full agonist of the serotonin 5-HT2C receptor ( = 35nM; = 94%), with 44-fold preference for activation of the serotonin 5-HT2C receptor over the serotonin 5-HT2A receptor. Whereas T-NBOMe had much higher affinity for the serotonin 5-HT2A receptor than tryptamine, it showed 89-fold lower activational potency at the serotonin 5-HT2A receptor than tryptamine and also had lower activational efficacy at the receptor. In an earlier study however, T-NBOMe showed much greater potency as an agonist of the serotonin 5-HT2A receptor ( = 155nM; = 44%).
The chemical synthesis of T-NBOMe has been described.
T-NBOMe was first described in the scientific literature by Ralf Heim and colleagues in 1999. It emerged as a novel designer drug by early 2024. However, the properties and effects of T-NBOMe in humans are unknown and it is unclear whether T-NBOMe actually produces hallucinogenic effects.
See also Substituted tryptamine N-Benzyltryptamine (T-NB; NBnT) 5-MeO-T-NBOMe 5-MeO-T-NB3OMe NEtPhOH-THPI
References
External links T-NBOMe - Isomer Design TNBOMe (HCl) / N-BOMe-Tryptamine HCl / - Bluelight